Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation

CompletedOBSERVATIONAL
Enrollment

737

Participants

Timeline

Start Date

June 15, 2017

Primary Completion Date

October 1, 2017

Study Completion Date

October 1, 2017

Conditions
Agitation,Psychomotor
Interventions
DRUG

Haloperidol Injection

As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.

DRUG

Ziprasidone Injection

As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.

DRUG

OLANZapine Injection

As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.

DRUG

Midazolam injection

As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.

Trial Locations (1)

55415

Hennepin County Medical Center, Minneapolis

All Listed Sponsors
lead

Hennepin Healthcare Research Institute

OTHER